Last reviewed · How we verify

NCT05311228

The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant

Completed Phase 4 Last updated 8 March 2024
What this trial tests

Phase 4 trial testing Azithromycin Powder in Bronchopulmonary Dysplasia in 120 participants. Completed in 1 April 2022.

Timeline
8 June 2021
Primary endpoint
1 March 2022
1 April 2022

Quick facts

Lead sponsorIndonesia University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment120
Start date8 June 2021
Primary completion1 March 2022
Estimated completion1 April 2022
Sites1 location across Indonesia

Drugs / interventions tested

Conditions studied

Sponsor

Indonesia University

Who can join

Adults 25 Weeks to 32 Weeks, any sex, with Bronchopulmonary Dysplasia or Intraventricular Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was to see the effectiveness of azithromycin in preventing the incidence of bronchopulmonary dysphasia in extremely preterm and very premature infants. Inclusion criteria were infants with a gestational age of 25-31 weeks 6 days who experienced respiratory distress and their families had agreed to participate in the study, then randomized. The intervention was in the form of giving azithromycin in the intervention group and no intervention was carried out in the control group and then followed up to 36 weeks PMA

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Azithromycin Powder

Trials testing the same drug.

Other recruiting trials for Bronchopulmonary Dysplasia

Currently open trials in the same condition.

Other Indonesia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05311228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing